drugset
drugset / Trial / NCT01626651

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants

NCT01626651 ↗

Phase 1 Completed 21 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the potential effects of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants.

Timeline

Start
2012-06
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibrutinib Small molecule 40 mg Oral
Subject Ketoconazole Small molecule 400 mg Oral

Indications

No indication recorded.